Five key drugs will have annual peak sales of €5.5 billion, says Bayer’s CEO

Hannah Blake


Bayer’s Management Board Chairman, Dr. Marijn Dekkers, believes that the pharmaceutical company’s five most promising new drugs will have an approximate peak annual sales potential of over €5.5 billion.

This sales forecast is comprised of deep vein thrombosis treatment, xarelto (rivaroxaban), macular edema drug, eylea (aflibercept), experimental prostate cancer drug alpharadin, colorectal cancer drug, stivarga, and high blood pressure treatment riociguat.

The Bayer Group is also currently seeing positive developments in its pharmaceuticals pipeline. In the last year, the Group has submitted more than 600 patent applications in the last year and is currently working on 35 clinical developments projects.

“Innovation is the only way to address the global challenges that exist at the beginning of the third millennium.

“To us, innovation always means generating value for our customers and society as a whole. Our mission sums it up: ‘Bayer: Science For A Better Life.’ In other words, our scientific successes are intended to help improve people’s lives.”

Bayer’s Management Board Chairman, Dr. Marijn Dekkers.

Dr. Marijn Dekkers announced Bayer’s positivity for the future at a recent press forum in Leverkusen, Germany.




Related news:

Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro (Reuters)

Reference links:

Bayer press release


Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.